# Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)

> **NCT07700303** · NA · NOT_YET_RECRUITING · sponsor: **University of Alberta** · enrollment: 78 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **PROCEDURE:** Discontinuation of parenteral prostacyclins analogues or selexipag

## Key facts

- **NCT ID:** NCT07700303
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2028-03-30
- **Final completion:** 2030-03-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700303, "Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*